Portfolio company Crescendo Biologics, the drug discovery and developer of Humabody™ VH therapeutics, has appointed Dr. Kevin Johnson as non-executive Chairman of the Board of Directors.
Dr Johnson has more than 25 years' experience in antibody development. Most recently, he has been on the Life Sciences team of Index Ventures since 2003, where he focused on drug development companies. Prior to this he held positions such as CTO of Cambridge Antibody Technology and CEO of Pangenetics (acquired by Abbott in 2009).
Dr Peter Pack, CEO of Crescendo, said:
“Kevin is a highly seasoned executive to head up our Board of Directors as we move the focus of the Company into the field of Oncology. His past experience is very relevant—from Cambridge Antibody Technologies where he was responsible for its antibody platform technologies to Pangenetics which specialised in taking antibodies from the late research stage through to clinical proof of concept. His input has already proved instrumental to the planning of our new strategy.”